Researchers evaluate possible mitochondrial factors in Alzheimer’s pathogenesis

A group of authors critically evaluated and interpreted the evidence linking mitochondrial dysfunction and metabolic changes to the pathogenesis of Alzheimer’s disease (AD).

PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – May 15, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on

May 15, 2024

MariMed Q1 Revenue Falls 4% Sequentially

MariMed Reports First Quarter 2023 Earnings NORWOOD, Mass., May 08, 2023 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a

May 9, 2023

PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow – Biotech Investments

PolyPeptide Group / Key word(s): Annual Results 12-March-2024 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is

March 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.